Cancer Advisor | One Day MD

Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146 (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer ( J Clin Oncol 2025 ) Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balsti...

Abstract Background: Fenbendazole, mebendazole and ivermectin have attracted interest as potential repurposed agents in oncology. Laboratory and preclinical studies provide biologically plausible mechanisms, but evidence for clinical efficacy in breast cancer remains insufficient for these drugs to be considered established anticancer treatments. Objective: This review restructures a publicly assembled archive of 130 breast-cancer case narratives into a hierarchical case-series classification system designed to identify recurring clinical patterns, sub-patterns, treatment combinations, metastatic distributions and reported response phenotypes. Methods: The archive was coded according to disease stage, recurrence status, breast-cancer subtype when reported, metastatic site, repurposed-drug exposure, conventional co-treatment, additional interventions, reported response and degree of objective verification. Cases were also classified according to whether the observed respo...

Introduction: Why This Debate Matters Right Now The metabolic theory of cancer is exploding in popularity. Professor Tom Seyfried has become a household name among patients seeking alternatives to conventional oncology, thanks to his groundbreaking book Cancer as a Metabolic Disease and the press-pulse strategy built around glucose and glutamine restriction. But in May 2026, Jane McLelland —bestselling author of How to Starve Cancer and a stage 4 cancer survivor who reversed her own disease—published an interesting Substack titled “ Beyond Warburg: What Tom Seyfried Gets Right — And the Blind Spot That Could Cost Your Patient. ” This isn’t a takedown. It’s a respectful, evidence-based extension that could save lives by highlighting a critical limitation in the “keto-for-everyone” approach. If you’re exploring ketogenic diet cancer protocols, repurposed drugs, or metabolic therapies, this article breaks it all down with actionable insights into the metabolic theory of canc...